Prostate Cancer

William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.

Continuing research will have to evaluate whether combining serum biomarkers or other measurable clinical factors with multiparametric magnetic resonance imaging results can help make negative or inaccurate prostate biopsies a rarity rather than the norm.

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. According to Mark Stein, MD, they can even serve as clinical endpoints in trials.

Identifying biomarkers to determine who should receive chemotherapy, targeted agents, and immunotherapy is just one of several obstacles the prostate cancer community is currently facing.

How oncologists can translate their increased understanding of the biology of prostate cancer into clinical practice is a question being raised currently in the field, explains Howard I. Scher, MD, adding, that the emergence of liquid biopsies could possibly be one way to tackle the issue.

A number of clinical trials are seeking to identify beneficial therapeutic outcomes in patients with prostate cancer who are resistant to androgen receptor–targeted agents.

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses next-generation antiandrogen therapies in metastatic castration-resistant prostate cancer (mCRPC).

As oncologists await the next major treatment advances in metastatic castration-resistant prostate cancer (mCRPC), the key in the interim is to optimize the available therapies, says Robert Dreicer, MD.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the use of novel circulating biomarkers in the treatment of patients with prostate cancer.

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses what novel combinatorial approaches researchers will be explored with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Philip W. Kantoff, MD, chairman of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the role that chemotherapy treatment with docetaxel will continue to have in patients with prostate cancer. Kantoff shared this insight in an interview during the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses understanding the genetics of patients with metastatic castration-resistant prostate cancer.

While immunotherapy continues to make headway in various malignancies, the chemotherapy docetaxel maintains a key role in the treatment of patients with metastatic prostate cancer.

Researchers have identified 3 distinct molecular subtypes of primary prostate cancer that correlate with distant metastasis-free survival and response to radiation therapy.

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses mitigating androgen receptor (AR)-resistance in patients with prostate cancer.

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses recent advancements in and what he sees on the horizon for metastatic castrate-resistant prostate cancer (mCRPC).

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the potential of combination regimens involving radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses genetic testing in prostate cancer.

The Large Urology Group Practice Association has announced the plan to create two alternative payment models that involve bundled payments.

David Albala, MD, discusses some of the benefits of robotic surgery and the impact it has had on the field of prostate cancer, as well as methods that larger urology groups can use to better achieve compliance.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.

Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discussed the use of fusion MRI in prostate cancer with OncLive during the LUGPA Annual Meeting.

Rahul Tendulkar, MD, associate staff, radiation oncology, Cleveland Clinic, discusses the side effects of a radical prostatectomy for men with prostate cancer.

The life expectancy of patients with metastatic castrate-resistant prostate cancer has doubled in recent years thanks to a multitude of new therapies, and there are still many more advancements to come.